JP3157165B2 - 抗腫瘍化合物、医薬組成物、それらの調製方法及び治療方法 - Google Patents
抗腫瘍化合物、医薬組成物、それらの調製方法及び治療方法Info
- Publication number
- JP3157165B2 JP3157165B2 JP52219294A JP52219294A JP3157165B2 JP 3157165 B2 JP3157165 B2 JP 3157165B2 JP 52219294 A JP52219294 A JP 52219294A JP 52219294 A JP52219294 A JP 52219294A JP 3157165 B2 JP3157165 B2 JP 3157165B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- carbon atoms
- phenyl
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- 238000002360 preparation method Methods 0.000 title description 25
- 230000000259 anti-tumor effect Effects 0.000 title description 9
- 229940123237 Taxane Drugs 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 37
- 229930190007 Baccatin Natural products 0.000 claims abstract description 4
- -1 isooctyl Chemical group 0.000 claims description 525
- 229910052739 hydrogen Inorganic materials 0.000 claims description 110
- 239000001257 hydrogen Substances 0.000 claims description 109
- 125000004432 carbon atom Chemical group C* 0.000 claims description 94
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 76
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 74
- 125000001072 heteroaryl group Chemical group 0.000 claims description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 52
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 49
- 125000003342 alkenyl group Chemical group 0.000 claims description 46
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 44
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 42
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 42
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 39
- 150000003952 β-lactams Chemical class 0.000 claims description 38
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 37
- 125000004122 cyclic group Chemical group 0.000 claims description 36
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 35
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 35
- 150000002431 hydrogen Chemical class 0.000 claims description 34
- 125000000304 alkynyl group Chemical group 0.000 claims description 32
- 125000002252 acyl group Chemical group 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 29
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 29
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 29
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 29
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 28
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 26
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 claims description 26
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 26
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 26
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 25
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 24
- 125000003944 tolyl group Chemical group 0.000 claims description 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 22
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 22
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 21
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 claims description 20
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 20
- 125000002541 furyl group Chemical group 0.000 claims description 20
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 20
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 19
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 19
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 19
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 18
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 125000003107 substituted aryl group Chemical group 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 18
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 17
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 16
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 16
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 15
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 15
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 15
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 15
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 15
- 125000003386 piperidinyl group Chemical group 0.000 claims description 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 15
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 15
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 15
- 229920002554 vinyl polymer Polymers 0.000 claims description 15
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 14
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 14
- 125000005110 aryl thio group Chemical group 0.000 claims description 14
- 239000004305 biphenyl Substances 0.000 claims description 14
- 235000010290 biphenyl Nutrition 0.000 claims description 14
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 14
- 125000001624 naphthyl group Chemical group 0.000 claims description 14
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 14
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 13
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 claims description 13
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 12
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 12
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical group C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 12
- 230000002194 synthesizing effect Effects 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 11
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 10
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 10
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 10
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 10
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 10
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 10
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 10
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 claims description 10
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- 125000000466 oxiranyl group Chemical group 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 10
- 125000001544 thienyl group Chemical group 0.000 claims description 10
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims description 8
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 7
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- ZMJJCODMIXQWCQ-UHFFFAOYSA-N potassium;di(propan-2-yl)azanide Chemical compound [K+].CC(C)[N-]C(C)C ZMJJCODMIXQWCQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- YHOBGCSGTGDMLF-UHFFFAOYSA-N sodium;di(propan-2-yl)azanide Chemical compound [Na+].CC(C)[N-]C(C)C YHOBGCSGTGDMLF-UHFFFAOYSA-N 0.000 claims description 6
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 5
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 5
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 5
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 5
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 5
- QQZOPKMRPOGIEB-UHFFFAOYSA-N n-butyl methyl ketone Natural products CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 claims description 5
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000005592 polycycloalkyl group Polymers 0.000 claims description 5
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 5
- 239000012312 sodium hydride Substances 0.000 claims description 5
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 5
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 5
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 3
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 11
- 125000005368 heteroarylthio group Chemical group 0.000 claims 10
- 238000001308 synthesis method Methods 0.000 claims 8
- 125000005587 carbonate group Chemical group 0.000 claims 4
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 claims 4
- 229910000103 lithium hydride Inorganic materials 0.000 claims 4
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 claims 4
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 claims 4
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- PYFHBOKDODRNSV-UHFFFAOYSA-N C1(=CC=CC=C1)C=C(CCC)C(C(OC=C=C=C=COC=C)=C(CCC)CCC)C(C(C(C(C)C)=C)(CC)CC)=C Chemical group C1(=CC=CC=C1)C=C(CCC)C(C(OC=C=C=C=COC=C)=C(CCC)CCC)C(C(C(C(C)C)=C)(CC)CC)=C PYFHBOKDODRNSV-UHFFFAOYSA-N 0.000 claims 3
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 claims 2
- 125000003963 dichloro group Chemical group Cl* 0.000 claims 2
- RSHAOIXHUHAZPM-UHFFFAOYSA-N magnesium hydride Chemical compound [MgH2] RSHAOIXHUHAZPM-UHFFFAOYSA-N 0.000 claims 2
- 229910012375 magnesium hydride Inorganic materials 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 235000014676 Phragmites communis Nutrition 0.000 claims 1
- 239000003610 charcoal Substances 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 1
- 238000010189 synthetic method Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 abstract description 8
- 239000002243 precursor Substances 0.000 abstract description 5
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 101
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 239000007787 solid Substances 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 238000004458 analytical method Methods 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 19
- 229930012538 Paclitaxel Natural products 0.000 description 19
- 239000003480 eluent Substances 0.000 description 19
- 229960001592 paclitaxel Drugs 0.000 description 19
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 150000002466 imines Chemical class 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- 229940063683 taxotere Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 4
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 4
- LUYQINUDJUXWNB-CLGJWYQZSA-N (3r,4s)-3-(1-ethoxyethoxy)-4-phenylazetidin-2-one Chemical compound N1C(=O)[C@H](OC(C)OCC)[C@@H]1C1=CC=CC=C1 LUYQINUDJUXWNB-CLGJWYQZSA-N 0.000 description 3
- FBZSDKXFQUKDLD-JGVFFNPUSA-N (3r,4s)-3-hydroxy-4-phenylazetidin-2-one Chemical compound N1C(=O)[C@H](O)[C@@H]1C1=CC=CC=C1 FBZSDKXFQUKDLD-JGVFFNPUSA-N 0.000 description 3
- UAXZZNDXCXGKHN-DLBZAZTESA-N (3r,4s)-4-phenyl-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound N1C(=O)[C@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]1C1=CC=CC=C1 UAXZZNDXCXGKHN-DLBZAZTESA-N 0.000 description 3
- ATGAAABKKYCMRZ-PKNBQFBNSA-N (e)-1-phenyl-n-trimethylsilylmethanimine Chemical compound C[Si](C)(C)\N=C\C1=CC=CC=C1 ATGAAABKKYCMRZ-PKNBQFBNSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000004705 aldimines Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ZMGDRBNFCBHSCX-SBKAZOPESA-N (3r,4s)-3-(1-ethoxyethoxy)-n,n-dimethyl-2-oxo-4-phenylazetidine-1-carboxamide Chemical compound CN(C)C(=O)N1C(=O)[C@H](OC(C)OCC)[C@@H]1C1=CC=CC=C1 ZMGDRBNFCBHSCX-SBKAZOPESA-N 0.000 description 2
- AWKAUVRITIXXDS-VHSXEESVSA-N (3r,4s)-3-hydroxy-4-(2-phenylethenyl)azetidin-2-one Chemical compound N1C(=O)[C@H](O)[C@@H]1C=CC1=CC=CC=C1 AWKAUVRITIXXDS-VHSXEESVSA-N 0.000 description 2
- MBLYSSFOVPQXBK-ZWKOTPCHSA-N (3r,4s)-4-(cyclohexylmethyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound N1C(=O)[C@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]1CC1CCCCC1 MBLYSSFOVPQXBK-ZWKOTPCHSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- ASMORJYLBRSZMH-UHFFFAOYSA-N C(C)OCCON1C(CC1C1=CC=CC=C1)=O Chemical compound C(C)OCCON1C(CC1C1=CC=CC=C1)=O ASMORJYLBRSZMH-UHFFFAOYSA-N 0.000 description 2
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241001116500 Taxus Species 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LZACTVWQMDJYGT-FCHUYYIVSA-N [(1r,2s)-2-phenylcyclohexyl] 2-tri(propan-2-yl)silyloxyacetate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OCC(=O)O[C@@H]1CCCC[C@H]1C1=CC=CC=C1 LZACTVWQMDJYGT-FCHUYYIVSA-N 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000003951 lactams Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- CNLLKNUDURSFQF-CXRLMVSZSA-N phenyl (3r,4s)-3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate Chemical compound N1([C@H]([C@H](C1=O)OC(C)OCC)C=1C=CC=CC=1)C(=O)OC1=CC=CC=C1 CNLLKNUDURSFQF-CXRLMVSZSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- AAIBYZBZXNWTPP-NWDGAFQWSA-N (1r,2s)-2-phenylcyclohexan-1-ol Chemical compound O[C@@H]1CCCC[C@H]1C1=CC=CC=C1 AAIBYZBZXNWTPP-NWDGAFQWSA-N 0.000 description 1
- VZWOPYKLCNUTOA-FCHUYYIVSA-N (3r,4s)-1-(4-methoxyphenyl)-4-(2-methylpropyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)[C@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]1CC(C)C VZWOPYKLCNUTOA-FCHUYYIVSA-N 0.000 description 1
- PMTRIMIXYUGLLG-PXWJKWRZSA-N (3r,4s)-3-(1-ethoxyethoxy)-1-(morpholine-4-carbonyl)-4-phenylazetidin-2-one Chemical compound N1([C@H]([C@H](C1=O)OC(C)OCC)C=1C=CC=CC=1)C(=O)N1CCOCC1 PMTRIMIXYUGLLG-PXWJKWRZSA-N 0.000 description 1
- HLGQGHAHARNBDF-CXRLMVSZSA-N (3r,4s)-3-(1-ethoxyethoxy)-2-oxo-n,4-diphenylazetidine-1-carboxamide Chemical compound N1([C@H]([C@H](C1=O)OC(C)OCC)C=1C=CC=CC=1)C(=O)NC1=CC=CC=C1 HLGQGHAHARNBDF-CXRLMVSZSA-N 0.000 description 1
- NXRYNKBJMXOXIU-CBMCFHRWSA-N (3r,4s)-3-(1-ethoxyethoxy)-4-(2-methylpropyl)azetidin-2-one Chemical compound CCOC(C)O[C@@H]1[C@H](CC(C)C)NC1=O NXRYNKBJMXOXIU-CBMCFHRWSA-N 0.000 description 1
- IXEWORORDXYHEL-SBKAZOPESA-N (3r,4s)-3-(1-ethoxyethoxy)-n-ethyl-2-oxo-4-phenylazetidine-1-carboxamide Chemical compound CCOC(C)O[C@H]1C(=O)N(C(=O)NCC)[C@H]1C1=CC=CC=C1 IXEWORORDXYHEL-SBKAZOPESA-N 0.000 description 1
- CNYWEOKDRLOJIZ-NTSWFWBYSA-N (3r,4s)-3-hydroxy-4-(2-methylpropyl)azetidin-2-one Chemical compound CC(C)C[C@@H]1NC(=O)[C@@H]1O CNYWEOKDRLOJIZ-NTSWFWBYSA-N 0.000 description 1
- FKDOEBRCIJFURM-RBUKOAKNSA-N (3r,4s)-4-(2-cyclohexylethyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound N1C(=O)[C@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]1CCC1CCCCC1 FKDOEBRCIJFURM-RBUKOAKNSA-N 0.000 description 1
- HMAYMAGIBRRASM-LSDHHAIUSA-N (3r,4s)-4-(2-methylpropyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound CC(C)C[C@@H]1NC(=O)[C@@H]1O[Si](C(C)C)(C(C)C)C(C)C HMAYMAGIBRRASM-LSDHHAIUSA-N 0.000 description 1
- QKSCWGBAQNDFDQ-RBUKOAKNSA-N (3r,4s)-4-(2-phenylethenyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound N1C(=O)[C@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]1C=CC1=CC=CC=C1 QKSCWGBAQNDFDQ-RBUKOAKNSA-N 0.000 description 1
- QMVSWLOIDKTZCH-LOSJGSFVSA-N (3r,4s)-4-(cyclohexylmethyl)-1-(4-methoxyphenyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)[C@H](O[Si](C(C)C)(C(C)C)C(C)C)[C@@H]1CC1CCCCC1 QMVSWLOIDKTZCH-LOSJGSFVSA-N 0.000 description 1
- CCUIHLAXXUSXHL-HEVMSJOKSA-N (3r,4s)-4-(cyclohexylmethyl)-3-(1-ethoxyethoxy)azetidin-2-one Chemical compound N1C(=O)[C@H](OC(C)OCC)[C@@H]1CC1CCCCC1 CCUIHLAXXUSXHL-HEVMSJOKSA-N 0.000 description 1
- HEXRCFLQWXZCKV-CLGJWYQZSA-N (3r,4s)-4-cyclohexyl-3-(1-ethoxyethoxy)azetidin-2-one Chemical compound N1C(=O)[C@H](OC(C)OCC)[C@@H]1C1CCCCC1 HEXRCFLQWXZCKV-CLGJWYQZSA-N 0.000 description 1
- KZMDAPKCKMCFEV-AOWWOYQVSA-N (3r,4s)-n-benzyl-3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxamide Chemical compound N1([C@H]([C@H](C1=O)OC(C)OCC)C=1C=CC=CC=1)C(=O)NCC1=CC=CC=C1 KZMDAPKCKMCFEV-AOWWOYQVSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VYWPOTRJNDKIDB-UHFFFAOYSA-N 1-(2-ethoxyethoxy)-4-(2-phenylethenyl)azetidin-2-one Chemical compound C(C)OCCON1C(CC1C=CC1=CC=CC=C1)=O VYWPOTRJNDKIDB-UHFFFAOYSA-N 0.000 description 1
- AWJLFKBCTHAJIN-UHFFFAOYSA-N 1-(4-methoxyphenyl)-4-[4-(trifluoromethyl)phenyl]-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(O[Si](C(C)C)(C(C)C)C(C)C)C1C1=CC=C(C(F)(F)F)C=C1 AWJLFKBCTHAJIN-UHFFFAOYSA-N 0.000 description 1
- FCBJLBCGHCTPAQ-UHFFFAOYSA-N 1-fluorobutane Chemical compound CCCCF FCBJLBCGHCTPAQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QISAUDWTBBNJIR-UHFFFAOYSA-N 2-phenylmethoxyacetyl chloride Chemical compound ClC(=O)COCC1=CC=CC=C1 QISAUDWTBBNJIR-UHFFFAOYSA-N 0.000 description 1
- LTSNEQGQJREXHW-UHFFFAOYSA-N 2-silyloxyacetic acid Chemical compound OC(=O)CO[SiH3] LTSNEQGQJREXHW-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- DAEVBIQJQVYXOM-UHFFFAOYSA-N 4,4-dimethoxycyclohexa-1,5-diene-1-carbaldehyde Chemical compound COC1(OC)CC=C(C=O)C=C1 DAEVBIQJQVYXOM-UHFFFAOYSA-N 0.000 description 1
- NRBGAMOMTGGWAN-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-(4-methoxyphenyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(O[Si](C(C)C)(C(C)C)C(C)C)C1C1=CC=C(F)C=C1 NRBGAMOMTGGWAN-UHFFFAOYSA-N 0.000 description 1
- RXAFQFGZUMFLQG-UHFFFAOYSA-N 4-(furan-2-yl)-1-(4-methoxyphenyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(O[Si](C(C)C)(C(C)C)C(C)C)C1C1=CC=CO1 RXAFQFGZUMFLQG-UHFFFAOYSA-N 0.000 description 1
- IXWWONGGCNWZCT-UHFFFAOYSA-N 4-[2-(furan-2-yl)ethenyl]-1-(4-methoxyphenyl)-3-tri(propan-2-yl)silyloxyazetidin-2-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(O[Si](C(C)C)(C(C)C)C(C)C)C1C=CC1=CC=CO1 IXWWONGGCNWZCT-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- MWKMQPSNTJCASD-UHFFFAOYSA-N 4-phenylazetidin-2-one Chemical compound N1C(=O)CC1C1=CC=CC=C1 MWKMQPSNTJCASD-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- AYNIQHSBIQOESF-JQXSQYPDSA-N CCOC(C)O[C@@H]1[C@@H](N(C1=O)C(=O)NOC(C)(C)C)C2=CC=CC=C2 Chemical compound CCOC(C)O[C@@H]1[C@@H](N(C1=O)C(=O)NOC(C)(C)C)C2=CC=CC=C2 AYNIQHSBIQOESF-JQXSQYPDSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YABDRNQRCVOCDW-QWHCGFSZSA-N [(1r,2s)-2-phenylcyclohexyl] 2-hydroxyacetate Chemical compound OCC(=O)O[C@@H]1CCCC[C@H]1C1=CC=CC=C1 YABDRNQRCVOCDW-QWHCGFSZSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- NWDNGTNUGMYFEQ-AOWWOYQVSA-N benzyl (3r,4s)-3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate Chemical compound N1([C@H]([C@H](C1=O)OC(C)OCC)C=1C=CC=CC=1)C(=O)OCC1=CC=CC=C1 NWDNGTNUGMYFEQ-AOWWOYQVSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- NBUYRJBENRNRNO-SBKAZOPESA-N ethyl (3r,4s)-3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate Chemical compound CCOC(=O)N1C(=O)[C@H](OC(C)OCC)[C@@H]1C1=CC=CC=C1 NBUYRJBENRNRNO-SBKAZOPESA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- PZOYNGVBODHSLH-HEVMSJOKSA-N methyl (3r,4s)-3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate Chemical compound COC(=O)N1C(=O)[C@H](OC(C)OCC)[C@@H]1C1=CC=CC=C1 PZOYNGVBODHSLH-HEVMSJOKSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 description 1
- 208000018962 mouth sore Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- CJCYABFPESVRKC-VIMPDCIZSA-N taxane ia Chemical compound O([C@H]1[C@H]2[C@@](C(C(=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 CJCYABFPESVRKC-VIMPDCIZSA-N 0.000 description 1
- QRCRZVITFSCZAR-PXWJKWRZSA-N tert-butyl (2s,3r)-2-(cyclohexylmethyl)-3-(1-ethoxyethoxy)-4-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(=O)[C@H](OC(C)OCC)[C@@H]1CC1CCCCC1 QRCRZVITFSCZAR-PXWJKWRZSA-N 0.000 description 1
- PLAUIGSDHJXQIK-JQXSQYPDSA-N tert-butyl (2s,3r)-2-cyclohexyl-3-(1-ethoxyethoxy)-4-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(=O)[C@H](OC(C)OCC)[C@@H]1C1CCCCC1 PLAUIGSDHJXQIK-JQXSQYPDSA-N 0.000 description 1
- PVKINVVDOGIDEK-LWNNLKQOSA-N tert-butyl (2s,3r)-3-(1-ethoxyethoxy)-2-(2-methylpropyl)-4-oxoazetidine-1-carboxylate Chemical compound CCOC(C)O[C@@H]1[C@H](CC(C)C)N(C(=O)OC(C)(C)C)C1=O PVKINVVDOGIDEK-LWNNLKQOSA-N 0.000 description 1
- WBVQQBOHJVFBFQ-MWSTZMHHSA-N tert-butyl (3r,4s)-3-(1-ethoxyethoxy)-2-oxo-4-(2-phenylethenyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(=O)[C@H](OC(C)OCC)[C@@H]1C=CC1=CC=CC=C1 WBVQQBOHJVFBFQ-MWSTZMHHSA-N 0.000 description 1
- CZTZICYNMYGUNU-JQXSQYPDSA-N tert-butyl (3r,4s)-3-(1-ethoxyethoxy)-2-oxo-4-phenylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(=O)[C@H](OC(C)OCC)[C@@H]1C1=CC=CC=C1 CZTZICYNMYGUNU-JQXSQYPDSA-N 0.000 description 1
- PDBCRPKYNWQALZ-QWHCGFSZSA-N tert-butyl (3r,4s)-3-acetyl-2-oxo-4-phenylazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(=O)[C@@H](C(=O)C)[C@H]1C1=CC=CC=C1 PDBCRPKYNWQALZ-QWHCGFSZSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/040,189 | 1993-03-26 | ||
| US08/040,189 US5475011A (en) | 1993-03-26 | 1993-03-26 | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
| US040,189 | 1993-03-26 | ||
| PCT/US1994/003215 WO1994022856A1 (en) | 1993-03-26 | 1994-03-24 | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10293599A Division JP3145993B2 (ja) | 1993-03-26 | 1999-04-09 | 抗腫瘍化合物及びその調製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08508497A JPH08508497A (ja) | 1996-09-10 |
| JP3157165B2 true JP3157165B2 (ja) | 2001-04-16 |
Family
ID=21909617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52219294A Expired - Fee Related JP3157165B2 (ja) | 1993-03-26 | 1994-03-24 | 抗腫瘍化合物、医薬組成物、それらの調製方法及び治療方法 |
| JP10293599A Expired - Fee Related JP3145993B2 (ja) | 1993-03-26 | 1999-04-09 | 抗腫瘍化合物及びその調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10293599A Expired - Fee Related JP3145993B2 (ja) | 1993-03-26 | 1999-04-09 | 抗腫瘍化合物及びその調製方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US5475011A (enExample) |
| EP (1) | EP0690856B1 (enExample) |
| JP (2) | JP3157165B2 (enExample) |
| KR (1) | KR100223720B1 (enExample) |
| CN (1) | CN1067682C (enExample) |
| AT (1) | ATE229018T1 (enExample) |
| AU (1) | AU676041B2 (enExample) |
| CA (1) | CA2158147C (enExample) |
| CZ (1) | CZ288924B6 (enExample) |
| DE (1) | DE69431833T2 (enExample) |
| DK (1) | DK0690856T3 (enExample) |
| ES (1) | ES2190440T3 (enExample) |
| HU (1) | HUT73848A (enExample) |
| NO (1) | NO311722B1 (enExample) |
| PL (2) | PL179587B1 (enExample) |
| PT (1) | PT690856E (enExample) |
| RU (1) | RU2137764C1 (enExample) |
| SK (1) | SK282317B6 (enExample) |
| WO (1) | WO1994022856A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015004022A (ja) * | 2013-06-24 | 2015-01-08 | 株式会社パイロットコーポレーション | 熱消色性筆記具インキ組成物及びそれを内蔵した筆記具 |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335362B1 (en) * | 1991-09-23 | 2002-01-01 | Florida State University | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them |
| US5475011A (en) * | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
| US6005120A (en) | 1993-07-20 | 1999-12-21 | Florida State University | Tricyclic and tetracyclic taxanes |
| FR2718137B1 (fr) * | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Procédé de préparation de trialcoylsilyl-7 baccatine III. |
| US5763477A (en) * | 1994-07-22 | 1998-06-09 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-β-hydroxy-10 deacetylbaccatin III |
| IT1275936B1 (it) * | 1995-03-17 | 1997-10-24 | Indena Spa | Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni |
| PT826688E (pt) * | 1995-04-28 | 2002-02-28 | Daiichi Seiyaku Co | Composto pentaciclico |
| IT1275435B (it) * | 1995-05-19 | 1997-08-07 | Indena Spa | Derivati della 10-desacetil-14beta-idrossibaccatina iii,loro metodo di preparazione e formulazioni che li contengono |
| EP0747372A1 (en) * | 1995-06-06 | 1996-12-11 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-beta-hydroxy-10 deacetybaccatin III |
| US5840748A (en) * | 1995-10-02 | 1998-11-24 | Xechem International, Inc. | Dihalocephalomannine and methods of use therefor |
| US5654448A (en) * | 1995-10-02 | 1997-08-05 | Xechem International, Inc. | Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes |
| US6177456B1 (en) | 1995-10-02 | 2001-01-23 | Xechem International, Inc. | Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor |
| US5854278A (en) * | 1995-12-13 | 1998-12-29 | Xechem International, Inc. | Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents |
| US5807888A (en) * | 1995-12-13 | 1998-09-15 | Xechem International, Inc. | Preparation of brominated paclitaxel analogues and their use as effective antitumor agents |
| US5688977A (en) * | 1996-02-29 | 1997-11-18 | Napro Biotherapeutics, Inc. | Method for docetaxel synthesis |
| AU737078C (en) | 1996-05-24 | 2002-05-02 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing diseases of body passageways |
| AU3572397A (en) * | 1996-07-02 | 1998-01-21 | Bristol-Myers Squibb Company | Ortho-ester analogs of paclitaxel |
| KR100225535B1 (ko) * | 1996-08-27 | 1999-10-15 | 정지석 | 파클리탁셀의 제조방법 |
| EP0868422A1 (de) * | 1996-09-24 | 1998-10-07 | Marigen S.A. | Ultramikroemulsionen aus spontan dispergierbaren konzentraten mit antitumoral und antiviral wirksamen estern von baccatin-iii-verbindungen |
| US6515016B2 (en) * | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| US5811452A (en) * | 1997-01-08 | 1998-09-22 | The Research Foundation Of State University Of New York | Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof |
| US7288665B1 (en) * | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| AU739303B2 (en) | 1997-08-21 | 2001-10-11 | Florida State University | Method for the synthesis of taxanes |
| US6235782B1 (en) | 1998-11-12 | 2001-05-22 | Rifat Pamukcu | Method for treating a patient with neoplasia by treatment with a platinum coordination complex |
| US6235776B1 (en) | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| ITMI991483A1 (it) * | 1999-07-06 | 2001-01-06 | Indena Spa | Derivati tassanici e procedimenti per la loro preparazione |
| HK1049787B (en) | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| CA2386772C (en) * | 1999-10-15 | 2009-01-13 | Daiichi Pharmaceutical Co., Ltd. | Pentacyclic taxane compound |
| DK1242401T3 (da) | 1999-11-24 | 2007-05-07 | Immunogen Inc | Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf |
| ATE432928T1 (de) * | 2000-02-02 | 2009-06-15 | Univ Florida State Res Found | C10-taxanester als antitumormittel |
| US6649632B2 (en) * | 2000-02-02 | 2003-11-18 | Fsu Research Foundation, Inc. | C10 ester substituted taxanes |
| CZ20013429A3 (cs) | 2000-02-02 | 2002-04-17 | Florida State University Research Foundation, Inc. | Taxany substituované v poloze C7 karbonátem jako protinádorová činidla |
| PL350028A1 (en) | 2000-02-02 | 2002-10-21 | Univ Florida State Res Found | C10 carbonate substituted taxanes as antitumor agents |
| US6916942B2 (en) * | 2000-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Process for the preparation of C-4 carbonate taxanes |
| US6750246B1 (en) * | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| IT1318678B1 (it) * | 2000-08-10 | 2003-08-27 | Indena Spa | Procedimento per la preparazione di derivati della baccatina iii. |
| IT1320107B1 (it) * | 2000-11-28 | 2003-11-18 | Indena Spa | Procedimento per la preparazione di derivati tassanici. |
| US6449899B1 (en) * | 2001-03-08 | 2002-09-17 | Council Of Scientific And Industrial Research | Method for inducing improved seed germination in Podophyllum hexandrum Royle |
| ITMI20012185A1 (it) * | 2001-10-19 | 2003-04-19 | Indena Spa | Procedimento per la preparazione della 14beta-idrossi-baccatina iii-1,14-carbonato |
| ITMI20012186A1 (it) * | 2001-10-19 | 2003-04-19 | Indena Spa | Procedimento per la preparazione della 14-beta-idrossi-baccatina iii-1,14-carbonato |
| RU2284328C2 (ru) * | 2001-11-29 | 2006-09-27 | Дайити Фармасьютикал Ко., Лтд. | Кристаллы производных таксана и способ их получения |
| WO2004013093A2 (en) * | 2002-08-02 | 2004-02-12 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| US7390898B2 (en) * | 2002-08-02 | 2008-06-24 | Immunogen Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| ITMI20021921A1 (it) | 2002-09-10 | 2004-03-11 | Indena Spa | Funzionalizzazione della posizione 14 dei nuclei tassanici e sintesi di nuovi derivati antitumorali. |
| ATE431343T1 (de) * | 2002-10-09 | 2009-05-15 | Chatham Biotec Ltd | Thio-analoga von paclitaxel und deren vorprodukte |
| US7064980B2 (en) * | 2003-09-17 | 2006-06-20 | Sandisk Corporation | Non-volatile memory and method with bit line coupled compensation |
| US7202370B2 (en) * | 2003-10-27 | 2007-04-10 | Conor Medsystems, Inc. | Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III |
| PE20050693A1 (es) * | 2004-02-13 | 2005-09-27 | Univ Florida State Res Found | Taxanos sustituidos con esteres de ciclopentilo en c10 |
| TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
| AU2004224925C1 (en) * | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| US7446126B2 (en) * | 2004-10-08 | 2008-11-04 | Indena S.P.A. | Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel |
| TW200640447A (en) * | 2005-02-14 | 2006-12-01 | Univ Florida State Res Found | C10 cyclopropyl ester substituted taxane compositions |
| US8263793B2 (en) * | 2005-03-31 | 2012-09-11 | Accord Healthcare Inc. | Preparation of taxanes from 9-dihydro-13-acetylbaccatin III |
| EP2647641A1 (en) * | 2005-11-04 | 2013-10-09 | Accord Healthcare Inc. | New methods for the preparation of taxanes using chiral auxiliaries |
| CN100516067C (zh) * | 2006-01-10 | 2009-07-22 | 上海恒瑞医药有限公司 | 具有抗肿瘤活性的紫杉酚衍生物 |
| US7615653B2 (en) * | 2006-03-15 | 2009-11-10 | The Research Foundation Of State University Of New York | Anti-tuberculosis taxane compounds |
| WO2008106491A2 (en) * | 2007-02-27 | 2008-09-04 | University Of Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
| RU2370261C2 (ru) * | 2007-08-03 | 2009-10-20 | Закрытое Акционерное Общество "Биокад" | Стабильная эмульсия для парентерального введения плохо растворимых в воде соединений, обладающих противоопухолевой активностью, и способ ее получения |
| RU2547939C2 (ru) * | 2007-12-26 | 2015-04-10 | Биотест Аг | Иммуноконъюгаты, направленные на cd138, и их применение |
| EP2238169A1 (en) * | 2007-12-26 | 2010-10-13 | Biotest AG | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
| PL2240516T3 (pl) * | 2007-12-26 | 2015-12-31 | Biotest Ag | Sposoby i środki do ulepszania nakierowania na komórki nowotworowe z ekspresją CD138 |
| CN101952315B (zh) | 2007-12-26 | 2015-04-01 | 生物测试股份公司 | 靶向cd138的试剂及其应用 |
| EP2080763A1 (en) * | 2008-01-18 | 2009-07-22 | INDENA S.p.A. | Crystalline form I of ortataxel |
| DK2080764T3 (da) | 2008-01-18 | 2012-09-24 | Indena Spa | Faste former af ortataxel |
| US8242166B2 (en) * | 2008-03-31 | 2012-08-14 | Florida State University Research Foundation, Inc. | C(10) ethyl ester and C(10) cyclopropyl ester substituted taxanes |
| US8236319B2 (en) | 2008-04-30 | 2012-08-07 | Immunogen, Inc. | Cross-linkers and their uses |
| CN104622809B (zh) | 2008-05-23 | 2019-04-19 | 英属哥伦比亚大学 | 用于脂质体纳米颗粒的修饰的药物 |
| CN101838281B (zh) * | 2010-05-20 | 2015-02-18 | 上海博速医药科技有限公司 | 一种多西他赛手性侧链中间体的制备方法 |
| WO2013018829A1 (ja) | 2011-08-02 | 2013-02-07 | アステラス製薬株式会社 | 薬剤の併用による癌治療方法 |
| EP2788030B1 (en) | 2011-12-08 | 2018-06-20 | Biotest AG | Uses of immunoconjugates targeting cd138 |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| CN104650109B (zh) * | 2013-11-22 | 2019-01-01 | 江苏天士力帝益药业有限公司 | 紫杉烷类化合物 |
| US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
| US9557445B2 (en) | 2015-02-24 | 2017-01-31 | Arkema France | Optical diffusion blend materials for LED lighting |
| CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| CN116143678A (zh) | 2016-11-14 | 2023-05-23 | 杭州多禧生物科技有限公司 | 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
| EP3755718A1 (en) | 2018-02-21 | 2020-12-30 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
| CN109485593A (zh) * | 2018-12-12 | 2019-03-19 | 福建紫杉园生物有限公司 | 一种拉洛他赛手性侧链的合成工艺 |
| KR20240095442A (ko) | 2021-11-03 | 2024-06-25 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 항체의 특이적 접합 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4876399A (en) * | 1987-11-02 | 1989-10-24 | Research Corporation Technologies, Inc. | Taxols, their preparation and intermediates thereof |
| FR2629819B1 (fr) * | 1988-04-06 | 1990-11-16 | Rhone Poulenc Sante | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii |
| US4857683A (en) * | 1988-12-28 | 1989-08-15 | W. H. Brady Co. | Membrane switchcores with key cell contact elements connected together for continuous path testing |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US5175315A (en) * | 1989-05-31 | 1992-12-29 | Florida State University | Method for preparation of taxol using β-lactam |
| US5015744A (en) * | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
| US5015722A (en) * | 1990-04-04 | 1991-05-14 | Hoechst Celanese Corporation | Melt-processable polyester capable of forming an anisotropic melt which exhibits a highly attractive balance between its molding and heat deflection temperatures |
| MX9102128A (es) * | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| IT1254517B (it) * | 1992-03-06 | 1995-09-25 | Indena Spa | 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico |
| FR2698363B1 (fr) * | 1992-11-23 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouveaux dérivés du taxane, leur préparation et les compositions qui les contiennent. |
| US5475011A (en) * | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
-
1993
- 1993-03-26 US US08/040,189 patent/US5475011A/en not_active Expired - Lifetime
-
1994
- 1994-03-24 ES ES94912300T patent/ES2190440T3/es not_active Expired - Lifetime
- 1994-03-24 AT AT94912300T patent/ATE229018T1/de active
- 1994-03-24 PL PL94310827A patent/PL179587B1/pl not_active IP Right Cessation
- 1994-03-24 AU AU64916/94A patent/AU676041B2/en not_active Ceased
- 1994-03-24 PL PL94338693A patent/PL180708B1/pl not_active IP Right Cessation
- 1994-03-24 RU RU95122773A patent/RU2137764C1/ru not_active IP Right Cessation
- 1994-03-24 JP JP52219294A patent/JP3157165B2/ja not_active Expired - Fee Related
- 1994-03-24 WO PCT/US1994/003215 patent/WO1994022856A1/en not_active Ceased
- 1994-03-24 PT PT94912300T patent/PT690856E/pt unknown
- 1994-03-24 EP EP94912300A patent/EP0690856B1/en not_active Expired - Lifetime
- 1994-03-24 CZ CZ19952480A patent/CZ288924B6/cs not_active IP Right Cessation
- 1994-03-24 DK DK94912300T patent/DK0690856T3/da active
- 1994-03-24 DE DE69431833T patent/DE69431833T2/de not_active Expired - Lifetime
- 1994-03-24 KR KR1019950704147A patent/KR100223720B1/ko not_active Expired - Fee Related
- 1994-03-24 SK SK1183-95A patent/SK282317B6/sk not_active IP Right Cessation
- 1994-03-24 HU HU9502642A patent/HUT73848A/hu not_active Application Discontinuation
- 1994-03-24 CN CN94192117A patent/CN1067682C/zh not_active Expired - Fee Related
- 1994-03-24 CA CA002158147A patent/CA2158147C/en not_active Expired - Fee Related
-
1995
- 1995-06-05 US US08/461,730 patent/US5599820A/en not_active Expired - Lifetime
- 1995-09-25 NO NO19953796A patent/NO311722B1/no not_active IP Right Cessation
- 1995-10-13 US US08/542,537 patent/US5705508A/en not_active Expired - Lifetime
-
1999
- 1999-04-09 JP JP10293599A patent/JP3145993B2/ja not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| Ｊ．Ｃｈｅｍ．Ｓｏｃ．，Ｐｅｒｋｉｎ Ｔｒａｎｓ．１，Ｎｏ．１４，ｐ．１５６３−１５６６（１９９３） |
| Ｊ．Ｍｅｄ．Ｃｈｅｍ．，Ｖｏｌ．３７，Ｎｏ．１０，ｐ．１４０８−１４１０（１９９４） |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015004022A (ja) * | 2013-06-24 | 2015-01-08 | 株式会社パイロットコーポレーション | 熱消色性筆記具インキ組成物及びそれを内蔵した筆記具 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3157165B2 (ja) | 抗腫瘍化合物、医薬組成物、それらの調製方法及び治療方法 | |
| US6100411A (en) | Taxoid anti-tumor agents and pharmaceutical compositions thereof | |
| JP3360186B2 (ja) | ６，７位を修飾したパクリタキセル類 | |
| US6096909A (en) | Taxoid anti-tumor agents and pharmaceutical compositions thereof | |
| JP3410518B2 (ja) | デオキシパクリタキセル類 | |
| EP1251846B1 (en) | C-4 carbonate taxanes | |
| US6201140B1 (en) | 7-0-ethers of taxane derivatives | |
| JPH08506339A (ja) | タキサン誘導体の製造法およびそのためのβ‐ラクタム中間体 | |
| US5767296A (en) | Deacetoxytaxol derivatives | |
| US6835746B2 (en) | Taxoid anti-tumor agents and pharmaceutical compositions thereof | |
| US6458976B1 (en) | Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods | |
| KR100223114B1 (ko) | 항종양화합물,그제조방법및용도 | |
| US20050250844A1 (en) | Methods of treating cancer using C-4 carbonate taxanes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090209 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100209 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100209 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100209 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110209 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110209 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120209 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130209 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140209 Year of fee payment: 13 |
|
| LAPS | Cancellation because of no payment of annual fees |